Just three months after quietly snuffing its late-stage development program for the cholesterol combo MK-0524B, Merck ($MRK) has doused development efforts on a new therapy combining its diabetes drug Januvia with a generic version of the cholesterol drug Lipitor .
About US
Contact us
